MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma

L. Fattore, A. Sacconi, R. Mancini, G. Ciliberto

Research output: Contribution to journalArticle

Abstract

microRNAs are major components of the eukaryotic post-transcriptional machinery and are frequently deregulated during cancer development. Increasing evidence points to them also as key players in the establishment of drug resistance. In this review, we provide an updated overview of the role of miRNAs in melanoma development and drug resistance and postulate that they are able to drive these processes in concert with deregulation of inflammatory and angiogenic cytokine expression. Notably, we have identified by querying the Cancer Genome Atlas database, a defined set of miRNAs which mostly have an impact on the development of melanoma and have recognized the main downstream pathways controlled by them. Most importantly, these miRNAs, which are down-regulated in metastatic melanomas as compared to primary tumors, are also able to predict prognosis of BRAF-mutated melanoma patients. Finally, we discuss the possibility that a common miRNA signature characterizes not only acquired resistance to MAPKi but also innate resistance to anti-PD-1 immunotherapy, since these conditions are both associated with alterations of the same pro-angiogenetic and pro-inflammatory pathways.
Original languageEnglish
Pages (from-to)39-48
Number of pages10
JournalCytokine and Growth Factor Reviews
Volume36
DOIs
Publication statusPublished - 2017

Fingerprint

Deregulation
MicroRNAs
Drug Resistance
Melanoma
Cytokines
Pharmaceutical Preparations
Neoplasms
Atlases
Immunotherapy
Machinery
Tumors
Genes
Genome
Databases

Keywords

  • Cytokines
  • Immunotherapy
  • Melanoma
  • Targeted therapies
  • miRNA

Cite this

MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. / Fattore, L.; Sacconi, A.; Mancini, R.; Ciliberto, G.

In: Cytokine and Growth Factor Reviews, Vol. 36, 2017, p. 39-48.

Research output: Contribution to journalArticle

@article{91218a73a7b64e7e9dbdabd7898e0f48,
title = "MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma",
abstract = "microRNAs are major components of the eukaryotic post-transcriptional machinery and are frequently deregulated during cancer development. Increasing evidence points to them also as key players in the establishment of drug resistance. In this review, we provide an updated overview of the role of miRNAs in melanoma development and drug resistance and postulate that they are able to drive these processes in concert with deregulation of inflammatory and angiogenic cytokine expression. Notably, we have identified by querying the Cancer Genome Atlas database, a defined set of miRNAs which mostly have an impact on the development of melanoma and have recognized the main downstream pathways controlled by them. Most importantly, these miRNAs, which are down-regulated in metastatic melanomas as compared to primary tumors, are also able to predict prognosis of BRAF-mutated melanoma patients. Finally, we discuss the possibility that a common miRNA signature characterizes not only acquired resistance to MAPKi but also innate resistance to anti-PD-1 immunotherapy, since these conditions are both associated with alterations of the same pro-angiogenetic and pro-inflammatory pathways.",
keywords = "Cytokines, Immunotherapy, Melanoma, Targeted therapies, miRNA",
author = "L. Fattore and A. Sacconi and R. Mancini and G. Ciliberto",
note = "LR: 20170625; CI: Copyright (c) 2017; JID: 9612306; OTO: NOTNLM; 2017/04/28 [received]; 2017/05/15 [accepted]; aheadofprint",
year = "2017",
doi = "S1359-6101(17)30059-X [pii]",
language = "English",
volume = "36",
pages = "39--48",
journal = "Cytokine and Growth Factor Reviews",
issn = "1359-6101",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma

AU - Fattore, L.

AU - Sacconi, A.

AU - Mancini, R.

AU - Ciliberto, G.

N1 - LR: 20170625; CI: Copyright (c) 2017; JID: 9612306; OTO: NOTNLM; 2017/04/28 [received]; 2017/05/15 [accepted]; aheadofprint

PY - 2017

Y1 - 2017

N2 - microRNAs are major components of the eukaryotic post-transcriptional machinery and are frequently deregulated during cancer development. Increasing evidence points to them also as key players in the establishment of drug resistance. In this review, we provide an updated overview of the role of miRNAs in melanoma development and drug resistance and postulate that they are able to drive these processes in concert with deregulation of inflammatory and angiogenic cytokine expression. Notably, we have identified by querying the Cancer Genome Atlas database, a defined set of miRNAs which mostly have an impact on the development of melanoma and have recognized the main downstream pathways controlled by them. Most importantly, these miRNAs, which are down-regulated in metastatic melanomas as compared to primary tumors, are also able to predict prognosis of BRAF-mutated melanoma patients. Finally, we discuss the possibility that a common miRNA signature characterizes not only acquired resistance to MAPKi but also innate resistance to anti-PD-1 immunotherapy, since these conditions are both associated with alterations of the same pro-angiogenetic and pro-inflammatory pathways.

AB - microRNAs are major components of the eukaryotic post-transcriptional machinery and are frequently deregulated during cancer development. Increasing evidence points to them also as key players in the establishment of drug resistance. In this review, we provide an updated overview of the role of miRNAs in melanoma development and drug resistance and postulate that they are able to drive these processes in concert with deregulation of inflammatory and angiogenic cytokine expression. Notably, we have identified by querying the Cancer Genome Atlas database, a defined set of miRNAs which mostly have an impact on the development of melanoma and have recognized the main downstream pathways controlled by them. Most importantly, these miRNAs, which are down-regulated in metastatic melanomas as compared to primary tumors, are also able to predict prognosis of BRAF-mutated melanoma patients. Finally, we discuss the possibility that a common miRNA signature characterizes not only acquired resistance to MAPKi but also innate resistance to anti-PD-1 immunotherapy, since these conditions are both associated with alterations of the same pro-angiogenetic and pro-inflammatory pathways.

KW - Cytokines

KW - Immunotherapy

KW - Melanoma

KW - Targeted therapies

KW - miRNA

U2 - S1359-6101(17)30059-X [pii]

DO - S1359-6101(17)30059-X [pii]

M3 - Article

VL - 36

SP - 39

EP - 48

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

SN - 1359-6101

ER -